Atopy

Early skin treatment in infants reduced weight and height compared with conventional approach

Suggests OA is not just about wear and tear

Disease status, itch improved significantly within 1 to 2 weeks with roflumilast cream

Black and multiracial children had the greatest increases in eczema

Key clinical outcomes, inflammatory biomarkers significantly reduced with or without steroids

With favorable results from three trials, approval seems likely

Elevated TARC at 2 months more than quadrupled the likelihood of moderate-severe AD at 2 years

Efficacy, safety maintained for up to 2 years in separate studies of tralokinumab

Small advantages for abrocitinib, upadacitinib, but data still accumulating for all the players

Rapid responses in a majority of patients in small trial of eblasakimab

EASI75 response rate exceeding 80% through 52 weeks of upadacitinib treatment

Atopic, metabolic, cardiovascular, and mental health conditions cited in guideline update

Once-daily abrocitinib and upadacitinib join topical ruxolitinib in expanding AD market

Clinicians faced with presumed dermatologic AEs urged to consider all differentials